Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.

European journal of clinical pharmacology - 1 Nov 2003

Sekino Kazuishi, Kubota Takahiro, Okada Yuko, Yamada Yasuhiko, Yamamoto Koujirou, Horiuchi Ryuya, Kimura Kenjirou, Iga Tatsuji

Abstract excerpt

OBJECTIVE: Losartan is metabolized to the active carboxylic acid metabolite EXP3174 by CYP2C9. In this study, we determined the effects of the single CYP2C9*3 variant on the pharmacokinetics and pharmacodynamics of losartan. METHODS: Seven healthy Japanese subjects ( CYP2C9*1/*1, n=4 and CYP2C9*1/*3, n=3) were phenotyped with a single dose of losartan (25 mg). Blood and urine samples were collected and assayed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antihypertensive Agents
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Pressure

Share to Cytochrome P-450 CYP2C9

Share to Heart Rate

Share to Imidazoles

Share to Losartan

Share to Tetrazoles

Source

Identifiers

PMID: 14504849
DOI: 10.1007/s00228-003-0664-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects.PMID 14504849Read ↗

Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.Semantic proximity Read ↗

Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.Semantic proximity Read ↗

Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174.Semantic proximity Read ↗

Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.Semantic proximity Read ↗

CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population.Semantic proximity Read ↗

CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.Semantic proximity Read ↗

Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype.Semantic proximity Read ↗

Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects.Semantic proximity Read ↗

[Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients].Semantic proximity Read ↗

In vitro and in vivo characterization of 13 CYP2C9 allelic variants found in Chinese Han population.Semantic proximity Read ↗

Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan.Semantic proximity Read ↗

Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.